Repurposed agents in the Alzheimer’s disease drug development pipeline

被引：0
作者：
Justin Bauzon
Garam Lee
Jeffrey Cummings
机构：
[1] University of Nevada,School of Medicine
[2] Las Vegas (UNLV),undefined
[3] Cleveland Clinic Lou Ruvo Center for Brain Health,undefined
[4] Chambers-Grundy Center for Transformative Neuroscience,undefined
[5] Department of Brain Health,undefined
[6] School of Integrated Health Sciences,undefined
[7] University of Nevada,undefined
[8] Las Vegas (UNLV),undefined
来源：
Alzheimer's Research & Therapy | / 12卷
关键词：
Alzheimer’s disease; Clinical trials; Repurposing; Dose; Formulation; Disease-modification;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 191 条
[1]  
Masters CL(2015)Alzheimer’s disease Nat Rev Dis Primers 1 15056-191
[2]  
Bateman R(2007)Forecasting the global burden of Alzheimer’s disease Alzheimers Dement 3 186-1395
[3]  
Blennow K(2009)Drug discovery. Repurposing with a difference Science. 324 1394-22
[4]  
Rowe CC(2013)A review: treatment of Alzheimer’s disease discovered in repurposed agents Dement Geriatr Cogn Disord 35 1-1321
[5]  
Sperling RA(2013)Drug repositioning: an opportunity to develop novel treatments for Alzheimer’s disease Pharmaceuticals (Basel) 6 1304-10
[6]  
Cummings JL(2019)CNS repurposing - potential new uses for old drugs: examples of screens for Alzheimer’s disease, Parkinson’s disease and spasticity Neuropharmacology. 147 4-1306
[7]  
Brookmeyer R(2017)Do cancer drugs counteract neurodegeneration? Repurposing for Alzheimer’s disease J Alzheimers Dis 55 1295-335
[8]  
Johnson E(2016)Bioinformatics methods in drug repurposing for Alzheimer’s disease Brief Bioinform 17 322-232
[9]  
Ziegler-Graham K(2016)Alzheimer’s drug-development pipeline: 2016 Alzheimers Dement (N Y). 2 222-384
[10]  
Arrighi HM(2017)Alzheimer’s disease drug development pipeline: 2017 Alzheimers Dement (N Y). 3 367-214
12345678910